Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2989718 | 0.91 | ALDH1A1 (0.44) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL1505073 | 0.88 | ALDH1A1 (0.42) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL8721639 | 0.88 | ALDH1A1 (0.42) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28293684 | 0.88 | ALDH1A1 (0.42) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28222242 | 0.86 | ALDH1A1 (0.40) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28538609 | 0.84 | ALDH1A1 (0.35) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL29185048 | 0.81 | FAAH (0.50) | ALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL4431540 | 0.80 | ALDH1A1 (0.35) | KCNJ1ALDH1A1L3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL4208428 | 0.80 | KCNJ1 (0.40) | KCNJ1ALDH1A1L3MBTL1GLAHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL60574 | 0.80 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-7057046-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | KCNJ1 3596/4885ALDH1A1 2808/4885L3MBTL1 1849/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | KCNJ1 3938/4885ALDH1A1 2992/4885L3MBTL1 3635/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | KCNJ1 3967/4885ALDH1A1 3723/4885L3MBTL1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.